Archive
546 articles, sorted by publication time.
Insilico Medicine and SK Biopharmaceuticals are directing their collaboration toward neuroimmune diseases, with a striking upper limit on deal value; but these diseases span the brain, immunity, and clinical subtyping, and real progress will still depend on whether targets can be supported by human evidence.
Licensing and investment partnerships between U.S. drugmakers and Chinese biotech companies are moving from commercial judgment toward the boundary of national security review; if a new draft bill advances, the division of labor in global new drug development may also be repriced.
As the pace of new drug development accelerates, manufacturing is also being forced to shift from fixed production lines to reconfigurable, scalable systems; the real test is balancing flexibility with quality audits.
An investment article has repackaged AI drug discovery as a tradable theme; the real scientific question is slower: whether algorithms can take attractive molecules into drugs that can be verified, manufactured, and pass the test in humans.
Clinical trials test not only whether a molecule works, but also whether a drug can reliably reach patients with auditable, distributable quality. Alpha1H’s latest progress marks a step from an R&D narrative toward late-stage clinical operations.
A tumor drug delivery platform has secured regulatory clearance and is preparing to enter early-stage clinical development in Abu Dhabi; the real test will shift from an engineering concept to safety, dosing, and performance in humans.
For patients with metastatic colorectal cancer who have already gone through multiple lines of treatment, efficacy is often measured in months. A large phase 3 trial showed that adding bevacizumab to trifluridine/tipiracil can push the limited space for later-line treatment a little further, but this is not a story of cure. It is a story of how evidence rewrites clinical options.
Hedge fund holdings have pushed AI drug discovery back into investors’ view; the truly new signal this time is not in the ranking itself, but in how the market is packaging data platforms, algorithm companies, and drug development risk into a single story.
A seemingly routine generic drug approval touches on access to medication during flu season: as the number of antiviral suppliers grows, pricing, inventory, and flexibility in clinical procurement may also be reshaped.
Datroway and Trodelvy have both shown an ability to delay disease worsening in clinical trials, giving some breast cancer patients the possibility of less traditional chemotherapy; the real questions remain which patients can benefit, how long the effects can last, and whether safety is sufficient to support a rewrite of treatment sequencing.
DelveInsight’s 2026 pipeline review puts several biotech companies on the soft tissue sarcoma R&D map; the real difficulty with this type of cancer is that multiple biological profiles are hidden under the disease name, and clinical breakthroughs often move more slowly and with more nuance than market report headlines suggest.
This is not a signal that AI drug development has already won, but a small step in moving a therapeutic candidate into an institutionalized development track; what will truly convince the medical community will still be subsequent experimental, toxicology, and clinical data.